A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL

The goal of this clinical trial is to evaluate the efficacy and safety of Lacutoclax, an oral selective BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Lacutoclax is a potent and selective BCL-2 inhibitor with relatively weaker inhibitory activity against BCL-XL and BCL-W. Preliminary clinical data have demonstrated promising efficacy and an acceptable safety profile in patients with CLL/SLL and other B-cell non-Hodgkin lymphomas (B-NHLs). This is an open-label, single-arm, multicenter Phase II study evaluating the eff

Trial Details

NCT ID
NCT07609823
Phase
PHASE2
Sponsor
Guangzhou Lupeng Pharmaceutical Company LTD.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Lacutoclax
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • Patients with confirmed R/R CLL/SLL according to the 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria.
  • Patients who had previously received standard therapy, experienced disease progression following the most recent line of treatment (excluding intol…
  • Have at least one measurable lesion.
  • Age ≥18 years, regardless of sex.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →